Prognostic value of sst2 in long-term mortality in acute heart failure.

IF 2.1 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Acta cardiologica Pub Date : 2024-09-24 DOI:10.1080/00015385.2024.2406683

Selcuk Matyar, Ayça Açıkalın Akpınar, Nezihat Rana Dişel, Akkan Avci, Çağlar Emre Çağlayan, Abdullah Yıldırım, Onur Akpınar

{"title":"Prognostic value of sst2 in long-term mortality in acute heart failure.","authors":"Selcuk Matyar, Ayça Açıkalın Akpınar, Nezihat Rana Dişel, Akkan Avci, Çağlar Emre Çağlayan, Abdullah Yıldırım, Onur Akpınar","doi":"10.1080/00015385.2024.2406683","DOIUrl":null,"url":null,"abstract":"Background: The use of biochemical markers in ADHF is considered valuable both in the diagnosis and treatment of diseases and in follow-up. This study aimed to investigate the prognostic power of serum sST2 and NT-proBNP levels in predicting long-term mortality in patients with ADHF using serial measurement.Methods: A total of 122 patients with ADHF were included in this prospective study. Venous blood samples were taken from the patients at the time of first admission to the emergency department and 48 h after hospitalisation. Serial measurements were performed using the same blood samples to determine NT-proBNP and sST2 levels.Results: The 1st time sST2 value was found to be significantly higher in the deceased group than in the living group, and this increase was found to be statistically significant (p < 0.001). The cut-off value for the 1st time value of sST2 was > 56.79 ng/mL, with 91.2% sensitivity and 79.5% specificity (area under the curve (AUC): 0.902, 95% confidence interval (CI): 0.835-0.948, p < 0.001). The cut-off value for the 2nd time sST2 value was > 38.91 ng/mL, with 97.1% sensitivity and 81.8% specificity (AUC: 0.932, 95% CI: 0.872-0.970, p < 0.001).Conclusion: In our study, sST2 gained value as a marker that should be included in panels with multiple markers. It seems more appropriate to recommend the serial measurement of sST2 in heart failure.Limitations of our study: The sample size is relatively small and there is no standard in timing and numbers in serial measurements.","PeriodicalId":6979,"journal":{"name":"Acta cardiologica","volume":" ","pages":"1-11"},"PeriodicalIF":2.1000,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta cardiologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/00015385.2024.2406683","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The use of biochemical markers in ADHF is considered valuable both in the diagnosis and treatment of diseases and in follow-up. This study aimed to investigate the prognostic power of serum sST2 and NT-proBNP levels in predicting long-term mortality in patients with ADHF using serial measurement.

Methods: A total of 122 patients with ADHF were included in this prospective study. Venous blood samples were taken from the patients at the time of first admission to the emergency department and 48 h after hospitalisation. Serial measurements were performed using the same blood samples to determine NT-proBNP and sST2 levels.

Results: The 1st time sST2 value was found to be significantly higher in the deceased group than in the living group, and this increase was found to be statistically significant (p < 0.001). The cut-off value for the 1st time value of sST2 was > 56.79 ng/mL, with 91.2% sensitivity and 79.5% specificity (area under the curve (AUC): 0.902, 95% confidence interval (CI): 0.835-0.948, p < 0.001). The cut-off value for the 2nd time sST2 value was > 38.91 ng/mL, with 97.1% sensitivity and 81.8% specificity (AUC: 0.932, 95% CI: 0.872-0.970, p < 0.001).

Conclusion: In our study, sST2 gained value as a marker that should be included in panels with multiple markers. It seems more appropriate to recommend the serial measurement of sST2 in heart failure.

Limitations of our study: The sample size is relatively small and there is no standard in timing and numbers in serial measurements.

查看原文本刊更多论文

SST2 对急性心力衰竭患者长期死亡率的预后价值。

背景：在 ADHF 中使用生化指标被认为对疾病的诊断、治疗和随访都很有价值。本研究旨在通过连续测量血清 sST2 和 NT-proBNP 水平来预测 ADHF 患者的长期死亡率：这项前瞻性研究共纳入了 122 名 ADHF 患者。患者在首次入住急诊科时和住院 48 小时后抽取静脉血样本。使用相同的血样进行连续测量，以确定 NT-proBNP 和 sST2 水平：结果：发现死亡组患者的第一次 sST2 值明显高于存活组患者，且这种增加具有统计学意义（p < 0.001）。sST2 首次值的临界值为 > 56.79 ng/mL，灵敏度为 91.2%，特异度为 79.5%（曲线下面积（AUC）：0.902，95% 置信度）：0.902，95% 置信区间 (CI)：0.835-0.948，p < 0.001）。第 2 次 sST2 值的临界值为 > 38.91 ng/mL，灵敏度为 97.1%，特异度为 81.8%（AUC：0.932，95% 置信区间（CI）：0.872-0.970，P <0.001）：在我们的研究中，sST2 作为一种标记物获得了更高的价值，应将其纳入多种标记物的组合中。我们研究的局限性：我们研究的局限性：样本量相对较小，连续测量的时间和次数没有标准。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta cardiologica 医学-心血管系统

CiteScore

2.50

自引率

12.50%

发文量

115

审稿时长

2 months

期刊介绍： Acta Cardiologica is an international journal. It publishes bi-monthly original, peer-reviewed articles on all aspects of cardiovascular disease including observational studies, clinical trials, experimental investigations with clear clinical relevance and tutorials.